ADVANCE – Accelerated development of vaccine benefit-risk collaboration in Europe

The goal of the ADVANCE project is to help health professionals, regulatory agencies, public health institutions, vaccine manufacturers and the general public make more informed decisions on benefits and risks of marketed vaccines. It will do this by creating a framework and tools to rapidly deliver reliable data on vaccine benefits and risks.

ADVANCE is a unique collaboration between key players in the sector, including European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), national public health and regulatory bodies, vaccine manufacturers, SMEs, and academic institutions.